• / Free eNewsletters & Magazine
  • / My Account
Home>Rare Disease Report® and CURE® Magazine Welcome the Fibrolamellar Cancer Foundation as a Strategic Alliance Partner

Rare Disease Report® and CURE® Magazine Welcome the Fibrolamellar Cancer Foundation as a Strategic Alliance Partner

Rare Disease Report® and CURE® Magazine Welcome the Fibrolamellar Cancer Foundation as a Strategic Alliance Partner

10/04/2017

Rare Disease Report ® and CURE® Magazine Welcome the Fibrolamellar Cancer Foundation as a Strategic Alliance Partner

The collaboration will work to enhance fibrolamellar hepatocellular carcinoma awareness

Rare Disease Report ® (RDR ® ) and CURE® magazine have joined forces with the Fibrolamellar Cancer Foundation (FCF) through the Strategic Alliance Partnership (SAP) program, announced Michael J. Hennessy Jr., president of Michael J. Hennessy Associates, parent company of RDR ® and CURE® magazine.

In making the announcement, Michael J. Hennessy Jr said, “We are thrilled to raise awareness for this rare type of liver cancer. FCF has been a pioneer in assisting patients affected by fibrolamellar hepatocellular carcinoma and exemplifies the fundamental principle that CURE® magazine was founded on: to assist patients as they navigate through their cancer journey. With this partnership, we aim to raise awareness and funds to enhance care for those affected by this rare disease.”

Fibrolamellar hepatocellular carcinoma (FHC) is an atypical liver cancer that impacts adolescents and young adults with no history of liver disease. As it only impacts 1 in 5 million individuals, it is considered ultra rare. Symptoms include abdominal, shoulder, or back pain; loss of appetite; weight loss; jaundice; and a palpable mass. Standard treatment includes surgical removal of the tumor or nonsurgical therapy.

“Strengthening awareness and fostering collaboration for ultra rare cancers such as fibrolamellar, is a critical part our the FCF’s mission,” states John Hopper, FCF President. “ The Strategic Alliance Partnership with Michael J. Hennessy Associates is ideal in meeting this goal today and in the future, for both healthcare professionals and the patient community.”

FCF is a charitable organization that channels 100% of its net donations to scientific research, striving to help spread awareness and support patients and their families. The organization was founded by Tucker Davis and his friends Alisha Sternenberger, Charles Beermann and Derek Gilchrist, in 2009 after Tucker was diagnosed with the disease. Little research was being conducted at the time on FHC, so the foundation’s mission was, and continues to be, three-fold:

  • Find a cure and treatment options
  • Raise awareness of FHC
  • Connect and support the fibrolamellar community of patients and their families

For more information on FCF, please visit www.raredr.com/sap-partner and www.curetoday.com/advocacy.

©2017 Morningstar Advisor. All right reserved.